IKT vs. ATYR, ALMS, ARCT, EOLS, BCYC, TECX, NBTX, CGEM, MBX, and PRME
Should you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include aTyr Pharma (ATYR), Alumis (ALMS), Arcturus Therapeutics (ARCT), Evolus (EOLS), Bicycle Therapeutics (BCYC), Tectonic Therapeutic (TECX), Nanobiotix (NBTX), Cullinan Therapeutics (CGEM), MBX Biosciences (MBX), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry.
Inhibikase Therapeutics vs. Its Competitors
aTyr Pharma (NASDAQ:ATYR) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 3.7% of aTyr Pharma shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
aTyr Pharma's return on equity of -93.69% beat Inhibikase Therapeutics' return on equity.
aTyr Pharma presently has a consensus target price of $23.25, indicating a potential upside of 332.16%. Inhibikase Therapeutics has a consensus target price of $6.50, indicating a potential upside of 261.11%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts clearly believe aTyr Pharma is more favorable than Inhibikase Therapeutics.
aTyr Pharma has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Inhibikase Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, aTyr Pharma had 7 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 8 mentions for aTyr Pharma and 1 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.67 beat aTyr Pharma's score of 0.75 indicating that Inhibikase Therapeutics is being referred to more favorably in the news media.
Summary
aTyr Pharma beats Inhibikase Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Inhibikase Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inhibikase Therapeutics Competitors List
Related Companies and Tools
This page (NYSE:IKT) was last updated on 8/29/2025 by MarketBeat.com Staff
MarketBeat All Access